StocksMedium•4 November 2026•
1 min read
Syndax Pharmaceuticals Revenue Jumps 82% in Q3 on Revuforj Sales Growth
Key Facts
1Syndax 3Q26 revenue surged 82% YoY to $83.3 million, driven by strong Revuforj sales.
2Revuforj sales grew 90% YoY, with management anticipating upside from post-transplant maintenance trends.
Syndax Pharmaceuticals Q3 2026 revenue surged 82% year-over-year to reach $83.3 million. Seeking Alpha reported that the growth was primarily driven by robust sales of its drug Revuforj, which saw a 90% increase compared to the same period last year.
SNDX closed at $14.29 on November 3, 2026, having reached a session high of $14.49. Company management anticipates further upside from Revuforj sales, citing strong commercial adoption and potential growth in post-transplant maintenance therapy trends.